These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 20434400)

  • 1. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
    Issels RD; Lindner LH; Verweij J; Wust P; Reichardt P; Schem BC; Abdel-Rahman S; Daugaard S; Salat C; Wendtner CM; Vujaskovic Z; Wessalowski R; Jauch KW; Dürr HR; Ploner F; Baur-Melnyk A; Mansmann U; Hiddemann W; Blay JY; Hohenberger P; ;
    Lancet Oncol; 2010 Jun; 11(6):561-70. PubMed ID: 20434400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
    Issels RD; Lindner LH; Verweij J; Wessalowski R; Reichardt P; Wust P; Ghadjar P; Hohenberger P; Angele M; Salat C; Vujaskovic Z; Daugaard S; Mella O; Mansmann U; Dürr HR; Knösel T; Abdel-Rahman S; Schmidt M; Hiddemann W; Jauch KW; Belka C; Gronchi A;
    JAMA Oncol; 2018 Apr; 4(4):483-492. PubMed ID: 29450452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current trials and new aspects in soft tissue sarcoma of adults.
    Issels RD; Schlemmer M
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study.
    Issels RD; Bosse D; Abdel-Rahman S; Starck M; Panzer M; Jauch KW; Stiegler H; Berger H; Sauer H; Peter K
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S233-7. PubMed ID: 8453705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.
    Schmitt T; Lehner B; Kasper B; Bischof M; Roeder F; Dietrich S; Dimitrakopoulou-Strauss A; Strauss LG; Mechtersheimer G; Wuchter P; Ho AD; Egerer G
    BMC Cancer; 2011 Dec; 11():510. PubMed ID: 22152120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
    Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
    Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
    Tap WD; Papai Z; Van Tine BA; Attia S; Ganjoo KN; Jones RL; Schuetze S; Reed D; Chawla SP; Riedel RF; Krarup-Hansen A; Toulmonde M; Ray-Coquard I; Hohenberger P; Grignani G; Cranmer LD; Okuno S; Agulnik M; Read W; Ryan CW; Alcindor T; Del Muro XFG; Budd GT; Tawbi H; Pearce T; Kroll S; Reinke DK; Schöffski P
    Lancet Oncol; 2017 Aug; 18(8):1089-1103. PubMed ID: 28651927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
    Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
    Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study.
    Issels RD; Abdel-Rahman S; Wendtner C; Falk MH; Kurze V; Sauer H; Aydemir U; Hiddemann W
    Eur J Cancer; 2001 Sep; 37(13):1599-608. PubMed ID: 11527684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study.
    Angele MK; Albertsmeier M; Prix NJ; Hohenberger P; Abdel-Rahman S; Dieterle N; Schmidt M; Mansmann U; Bruns CJ; Issels RD; Jauch KW; Lindner LH
    Ann Surg; 2014 Nov; 260(5):749-54; discussion 754-6. PubMed ID: 25379845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas.
    Wendtner CM; Abdel-Rahman S; Krych M; Baumert J; Lindner LH; Baur A; Hiddemann W; Issels RD
    J Clin Oncol; 2002 Jul; 20(14):3156-64. PubMed ID: 12118030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
    Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
    Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
    Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.
    Bonvalot S; Gronchi A; Le Péchoux C; Swallow CJ; Strauss D; Meeus P; van Coevorden F; Stoldt S; Stoeckle E; Rutkowski P; Rastrelli M; Raut CP; Hompes D; De Paoli A; Sangalli C; Honoré C; Chung P; Miah A; Blay JY; Fiore M; Stelmes JJ; Dei Tos AP; Baldini EH; Litière S; Marreaud S; Gelderblom H; Haas RL
    Lancet Oncol; 2020 Oct; 21(10):1366-1377. PubMed ID: 32941794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
    Marina NM; Smeland S; Bielack SS; Bernstein M; Jovic G; Krailo MD; Hook JM; Arndt C; van den Berg H; Brennan B; Brichard B; Brown KLB; Butterfass-Bahloul T; Calaminus G; Daldrup-Link HE; Eriksson M; Gebhardt MC; Gelderblom H; Gerss J; Goldsby R; Goorin A; Gorlick R; Grier HE; Hale JP; Hall KS; Hardes J; Hawkins DS; Helmke K; Hogendoorn PCW; Isakoff MS; Janeway KA; Jürgens H; Kager L; Kühne T; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Meyers PA; Mottl H; Nathrath M; Papai Z; Randall RL; Reichardt P; Renard M; Safwat AA; Schwartz CL; Stevens MCG; Strauss SJ; Teot L; Werner M; Sydes MR; Whelan JS
    Lancet Oncol; 2016 Oct; 17(10):1396-1408. PubMed ID: 27569442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
    Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
    Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia.
    Wendtner C; Abdel-Rahman S; Baumert J; Falk MH; Krych M; Santl M; Hiddemann W; Issels RD
    Eur J Cancer; 2001 Sep; 37(13):1609-16. PubMed ID: 11527685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.